WallStSmart

Agilent Technologies Inc (A)vsIQVIA Holdings Inc (IQV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 130% more annual revenue ($16.98B vs $7.37B). A leads profitability with a 19.5% profit margin vs 8.1%. IQV appears more attractively valued with a PEG of 0.97. A earns a higher WallStSmart Score of 63/100 (C+).

A

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 8.5Value: 4.7Quality: 6.0
Piotroski: 3/9Altman Z: 1.99

IQV

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 6.0Quality: 3.0
Piotroski: 2/9Altman Z: 1.23
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-65.8%)

Margin of Safety

-65.8%

Fair Value

$77.73

Current Price

$156.47

$78.74 premium

UndervaluedFair: $77.73Overvalued
IQVUndervalued (+12.0%)

Margin of Safety

+12.0%

Fair Value

$201.30

Current Price

$266.42

$65.12 discount

UndervaluedFair: $201.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A1 strengths · Avg: 8.0/10
Operating MarginProfitability
25.6%8/10

Strong operational efficiency at 25.6%

IQV2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.3%9/10

Every $100 of equity generates 22 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

Areas to Watch

A3 concerns · Avg: 3.7/10
P/E RatioValuation
29.0x4/10

Moderate valuation

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

IQV4 concerns · Avg: 2.8/10
P/E RatioValuation
31.9x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-0.6%2/10

Earnings declined 0.6%

Altman Z-ScoreHealth
1.232/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on Operating Margin. Profitability is solid with margins at 19.5% and operating margin at 25.6%. PEG of 1.25 suggests the stock is reasonably priced for its growth.

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bear Case : A

The primary concerns for A are P/E Ratio, Altman Z-Score, Piotroski F-Score.

Bear Case : IQV

The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.63 is elevated, increasing financial risk.

Key Dynamics to Monitor

A profiles as a mature stock while IQV is a value play — different risk/reward profiles.

A carries more volatility with a beta of 1.24 — expect wider price swings.

IQV is growing revenue faster at 8.7% — sustainability is the question.

A generates stronger free cash flow (439M), providing more financial flexibility.

Bottom Line

A scores higher overall (63/100 vs 55/100), backed by strong 19.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Want to dig deeper into these stocks?